Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490089 | 0.88 | BRD4 (0.54) | BRD4CREBBPTRPV1 | |
| SCHEMBL21932292 | 0.84 | BRD4 (0.56) | BRD4CREBBPTRPV1 | |
| SCHEMBL4117446 | 0.81 | MAPT (0.41) | NPC1MAPTRAB9ATRPV1HSD17B1 | |
| SCHEMBL13090753 | 0.77 | BRD4 (0.61) | BRD4CREBBPTRPV1 | |
| SCHEMBL15053395 | 0.77 | TRPV1 (0.53) | BRD4CREBBPTRPV1 | |
| SCHEMBL4123040 | 0.76 | BRD4 (0.76) | BRD4CREBBPTRPV1 | |
| SCHEMBL27554931 | 0.76 | BRD4 (0.59) | BRD4CREBBPTRPV1 | |
| SCHEMBL3599751 | 0.76 | BRD4 (0.59) | BRD4CREBBPMAPTTRPV1 | |
| SCHEMBL14521036 | 0.76 | CRBN (0.60) | NPC1MAPTRAB9AHSD17B1 | |
| SCHEMBL3604431 | 0.76 | BRD4 (0.59) | BRD4CREBBPTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2260026-B1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | BRD4 164/4885CREBBP 2730/4885NPC1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.